Psychiatric Genomics of Gaithersburg, Md., which uses gene expression analysis of brain and other human tissues to develop medications for mental illness, has appointed Bradley Lorimier to its board of directors and as a business development consultant. Lorimer currently consults within the pharmaceutical industry and serves on the boards of four companies. Lorimer retired from his position as senior vice president of business development for Human Genome Sciences in 1997.